TXNIP Suppresses Lung Cancer Progression by Inhibiting TRAF6-Mediated NF-κB Activation and Autophagy

Area of Science:

• Oncology
• Molecular Biology
• Cellular Signaling

Background:

• Thioredoxin-interacting protein (TXNIP) is a known tumor suppressor, but its specific role in lung cancer pathogenesis is not well understood.
• Tumor necrosis factor receptor-associated factor 6 (TRAF6)-mediated NF-κB activation and autophagy are critical pathways implicated in lung cancer progression.

Purpose of the Study:

• To elucidate the function of TXNIP in lung cancer.
• To investigate the regulatory relationship between TXNIP, TRAF6, NF-κB signaling, and autophagy in lung cancer cells.

Main Methods:

• Protein-protein interaction assays to determine TXNIP-TRAF6 binding.
• Western blotting and ubiquitination assays to assess protein modifications.
• Gene expression analysis using public datasets and patient tissues.
• Cellular assays (proliferation, migration, invasion, colony formation) in TXNIP-knockout lung cancer cells.
• NF-κB activity and cytokine production measurements after Toll-like receptor stimulation.

Main Results:

• TXNIP directly binds TRAF6, inhibiting its dimerization and auto-ubiquitination, thereby suppressing NF-κB and autophagy.
• TXNIP expression is significantly downregulated in lung adenocarcinoma and squamous cell carcinoma.
• Lower TXNIP and higher TRAF6 expression in non-small cell lung cancer patients is associated with increased metastasis and poorer survival.
• TXNIP deficiency enhances TRAF6 and beclin 1 ubiquitination, NF-κB activity, and pro-tumorigenic cellular functions.

Conclusions:

• TXNIP acts as a crucial suppressor of oncogenic TRAF6-driven pathways in lung cancer.
• Downregulation of TXNIP contributes to lung cancer progression by enhancing Toll-like receptor-induced signaling, NF-κB activation, and autophagy.